Neurosense TherapeuticsNRSN
13F holders, Q3 2025 (September 30)10holders −7
1new positions
8sold out
$1.25avg. 13F price*
At the end of Q3 2025, 10 institutions reported holding Neurosense Therapeutics Ltd. (NRSN) in their 13F filings, down 7 from Q2 2025. 1 opened new positions and 8 sold out. The largest holders were Squarepoint Ops LLC ($119K), Morgan Stanley ($83K) and Meitav Investment House Ltd. ($50K).
- Company
- Neurosense Therapeutics Ltd.
- CUSIP
- M74240108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $26K |
| Exits | 8 | $539K |
All 13F filers, Q2 2025 → Q3 2025: 79,584 shares bought and 311,703 shares sold, net −232,119 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Squarepoint Ops LLC | 0.00% | Add +91.0% | 95,375 | $119K |
| Morgan Stanley | 0.00% | Reduce -16.9% | 66,400 | $83K |
| Meitav Investment House Ltd. | 0.00% | No change | 40,000 | $50K |
| Two Sigma Investments, LP | 0.00% | New | 21,086 | $26K |
| Commonwealth Equity Services, LLC | 0.00% | No change | 21,080 | $26K |
| Geode Capital Management, LLC | 0.00% | No change | 15,870 | $20K |
| UBS Group AG | 0.00% | Add +809.9% | 14,659 | $18K |
| SBI Securities Co., Ltd. | 0.00% | Reduce -67.3% | 1,455 | $2K |
| Jones Financial Companies LLLP | 0.00% | Reduce -90.8% | 1,000 | $1K |
| Cwm, LLC | 0.00% | No change | 1,000 | $1K |
"% of holder's portfolio" is NRSN's weight in each manager's 13F, not the share of Neurosense Therapeutics Ltd. the manager owns.